--- title: 'Industry Daily Summary: What Happened on October 15, 2026' headline: Alentis, PinotBio pair up on claudin-1 cancer ADCs description: Verastem also set out a succession plan for its chief executive role. url: https://thebench.bio/news/industry/2026-10-15 topic: industry date: '2026-10-15' covers: - '2026-10-15' date_published: '2026-10-15T12:04:19Z' date_modified: '2026-10-15T12:04:19Z' tags: - Industry sources: 2 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on October 15, 2026 **Alentis, PinotBio pair up on claudin-1 cancer ADCs** Verastem also set out a succession plan for its chief executive role. ## Today in brief Alentis Therapeutics and South Korea’s PinotBio signed a research and licensing agreement to develop antibody-drug conjugates for cancers that express claudin-1. [1] Alentis has an exclusive option to license PinotBio’s linkers and payloads. PinotBio is eligible for upfront, development, regulatory and commercial milestone payments, plus royalties on net sales. [1] Verastem disclosed a plan for succession in its chief executive role. [2] ## Also worth knowing - Alentis is evaluating two claudin-1 antibody-drug conjugates in Phase I/II trials. The FDA granted fast track designation to ALE.P02 for advanced or metastatic claudin-1-positive squamous tumors. [1] ## Also published - [Changing Faces: Agency, consultancy, and investor hires, August and September 2026](), pharmaphorum - [Could OMass become the UK's 'big biotech' company?](), pharmaphorum - [EUCOPE Member Spotlight: Q&A with Dan Staner, President, Region Europe](), EUCOPE ## Sources 1. [Alentis and PinotBio partner to develop claudin-1 oncology ADCs](), Pharmaceutical Technology, 2026-10-15 2. [Verastem reveals CEO succession plan](), BioCentury, 2026-10-15 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: